Michael Sacerdote
Biotech

MacroGenics: Big Dreams, Good Molecules

Although the IPO market has become relatively frothy, the opportunity remains for biotech investors who carefully vet the offerings to buy great science on the cheap. This week, MacroGenics (NASDAQ:MGNX) brings solid drug prospects, albeit in a highly competitive opportunity space. Using conservative risk discounting, I estimate the true value of the company to be $568-$628 million, or $21.85-$24.15 per share.

Underlying technology

While MacroGenics is like many other young biotech companies in that one prospect dominates its valuation, MacroGenics also owns bona fide development platforms for further drug discovery beyond its lead compound. MacroGenics has two core scientific platforms for drug discovery: Fc-optimized antibodies and dual affinity re-targeted antibody-related molecules (DARTs).

(click to enlarge)

Figure 1. Pipeline....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details